Medical Xpress - Cardiology

APRIL 11, 2024

military veterans with diabetes to validate and modify a widely accepted model used to predict the risk of heart failure in diabetic patients. A recent study by Case Western Reserve University used national data from U.S.

Heart Failure 98

Heart Failure Diabetes 98

Heart BMJ

MARCH 26, 2025

Heart failure (HF) is one of the significant complications in patients with myocardial infarction (MI), leading to increased risk for cardiovascular morbidity and mortality. Common predictors include older age, prior hypertension, diabetes and atrial fibrillation. HFrEF is more commonly.

Myocardial Infarction 52

Myocardial Infarction Preserved Ejection Fraction Heart Failure Aortic valve 52

Cardiovascular Diabetology

NOVEMBER 19, 2024

Diabetic heart disease may eventually lead to heart failure, a leading cause of mortality in diabetic individuals. The lack of effective treatments for diabetes-induced heart failure may result from a failure.

Diabetes 105

Diabetes Heart Failure Heart Disease Research 105

DAIC

JUNE 21, 2024

announced that the peer-reviewed Journal of the American College of Cardiology: Heart Failure has published a research paper concluding that INPEFA (sotagliflozin) is cost-effective for people with diabetes and recent worsening heart failure using commonly accepted willingness-to-pay thresholds. “Our

Heart Failure 105

Heart Failure Preserved Ejection Fraction Diabetes Research 105

Medical Xpress - Cardiology

JANUARY 2, 2024

A two-step screening protocol that combines clinical risk assessment with biomarker testing can more effectively identify which patients with type 2 diabetes need medication to prevent heart failure, according to a study led by UT Southwestern Medical Center researchers.

Heart Failure 78

Heart Failure Diabetes Biomarkers Research 78

Science Daily - Heart Disease

MARCH 5, 2025

Research shows that a common type of diabetes medication could help cancer patients make a better long-term recovery. Many cancer patients go on to develop heart failure -- because of the cancer itself and also due to chemotherapy.

Cancer 99

Cancer Diabetes Heart Failure Research 99

Med Page Today

JANUARY 11, 2025

(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center.

Heart Failure 98

Heart Failure Exercise Diabetes 98

Science Daily - Heart Disease

JULY 24, 2024

In mice with heart failure with preserved ejection fraction (HFpEF), increasing ketone supply to the heart allowed their hearts to utilize more ketones and produce more energy.

Preserved Ejection Fraction 117

Preserved Ejection Fraction Diabetes Heart Failure 117

Cardiovascular Diabetology

MARCH 21, 2025

Mineralocorticoid receptor antagonists (MRAs) are often underutilized in patients with heart failure (HF), particularly those with diabetes and/or chronic kidney disease (CKD). However, the impact of concurren.

Kidney Disease 59

Kidney Disease Heart Failure Diabetes Hospital 59

HCPLive

MARCH 31, 2025

Justin Mark, MD, discusses an analysis of the FIGHT trial looking at racial and ethnic differences in heart failure outcomes.

Heart Failure 69

Heart Failure Outcomes Diabetes 69

Med Page Today

APRIL 7, 2024

(MedPage Today) -- ATLANTA -- Weight loss and heart failure benefits with semaglutide (Wegovy) extended to patients with obesity-related heart failure with preserved ejection fraction (HFpEF) who have type 2 diabetes, the STEP-HFpEF DM trial showed.

Preserved Ejection Fraction 88

Preserved Ejection Fraction Diabetes Heart Failure Obesity 88

American College of Cardiology

APRIL 6, 2024

The goal of the STEP-HFpEF DM trial was to compare the safety and efficacy of semaglutide among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM).

Preserved Ejection Fraction 69

Preserved Ejection Fraction Heart Failure Obesity Diabetes 69

Cardiovascular Diabetology

AUGUST 6, 2024

Objective To explore trends in prognosis and use of glucose-lowering drugs (GLD) in patients with diabetes and coronary artery disease (CAD). Research design and methods All patients with diabetes and CAD undergoing a coronary angiography between 2010 and 2021 according to the Swedish Angiography and Angioplasty Registry were included.

Coronary Artery Disease 98

Coronary Artery Disease Diabetes Myocardial Infarction Heart Failure 98

HCPLive

JUNE 18, 2024

New research from the SOLOST-WHF trial suggests sotagliflozin is a cost-effective treatment for diabetes patients with recent heart failure, with high cost-effectiveness probability.

Heart Failure 69

Heart Failure Diabetes Research 69

Cardiovascular Diabetology

JANUARY 8, 2024

Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal diseases (CVRD) manifestations for type 2 diabetes.

Peripheral Arterial Disease 105

Peripheral Arterial Disease Myocardial Infarction Kidney Disease Diabetes 105

Medical Xpress - Cardiology

DECEMBER 30, 2023

For patients with heart failure and type 2 diabetes (T2D), dapagliflozin does not reduce urinary albumin-to-creatinine ratio (UACR) but does reduce some cardiovascular events, according to a study published online Nov. 27 in eClinicalMedicine.

Heart Failure 74

Heart Failure Diabetes 74

Cardiovascular Diabetology

JANUARY 19, 2024

Diabetes mellitus (DM) is associated with a worse prognosis in patients with heart failure. Our aim was to analyze the clinical and imaging features of patients with DM and their association with outcomes in c.

Diabetes 95

Diabetes Outcomes Heart Failure Cardiomyopathy 95

DAIC

APRIL 9, 2024

Decline in exercise ability is a hallmark of progression to overt heart failure. The international ARISE-HF trial was designed to test the effectiveness of the investigational drug AT-001 at stabilizing exercise capacity in patients with diabetic cardiomyopathy. Patients had had Type 2 diabetes for an average of 14 years.

Heart Failure 52

Heart Failure Diabetes Cardiomyopathy Exercise 52

Science Daily - Heart Disease

FEBRUARY 14, 2025

New research shows sotagliflozin is the only drug in its class to demonstrate these results.

Heart Attack 114

Heart Attack Heart attacks Kidney Disease Heart Failure 114

Cardiovascular Diabetology

JUNE 14, 2024

Diabetic kidney disease is an established risk factor for heart failure. However, the impact of incident heart failure on the subsequent risk of renal failure has not been systematically assessed in diabetic p.

Kidney Disease 52

Kidney Disease Heart Failure Diabetes Risk Factors 52

Cardiovascular Diabetology

MARCH 20, 2025

The triglyceride-glucose index serves as a dependable biomarker for gauging insulin resistance linked to cardiovascular disease. Our study was designed to investigate how the trajectory of the triglyceride-glu.

Heart Failure 86

Heart Failure Biomarkers Cardiovascular Disease Diabetes 86

Cardiovascular Diabetology

AUGUST 30, 2024

Heart failure with preserved ejection fraction (HFpEF) is common in type 2 diabetes mellitus (T2D), leading to high morbidity and mortality. Managing HFpEF in diabetic patients is challenging with limited trea.

Preserved Ejection Fraction 59

Preserved Ejection Fraction Heart Failure Diabetes Research 59

European Journal of Heart Failure

NOVEMBER 26, 2024

Discontinuation and reinitiation of mineralocorticoid receptor antagonists (MRA) in patients with heart failure and reduced ejection fraction (HFrEF). BMI, body mass index; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association. 1.34), ischaemic heart disease (HR 1.20, 95% CI 1.09–1.31),

Heart Failure 71

Heart Failure Kidney Disease Atrial Fibrillation BMI 71

Cardiovascular Diabetology

JUNE 6, 2024

Sodium glucose cotransporter 2 (SGLT2) inhibitors significantly improve cardiovascular outcomes in diabetic patients; however, the mechanism is unclear. We hypothesized that dapagliflozin improves cardiac outc.

Diabetes 64

Diabetes Heart Failure Outcomes Research 64

Cardiovascular Diabetology

APRIL 28, 2024

Glycemic control, as measured by glycosylated hemoglobin (HbA1c), is an important biomarker to evaluate diabetes severity and is believed to be associated with heart failure development. Type 2 diabetes mellit.

Heart Failure 52

Heart Failure Diabetes Biomarkers Outcomes 52

American College of Cardiology

NOVEMBER 7, 2024

The goal of the EMPEROR-Preserved trial was to assess the safety and efficacy of empagliflozin in patients with symptomatic heart failure with preserved ejection fraction (HFpEF), irrespective of diabetes status.

Preserved Ejection Fraction 61

Preserved Ejection Fraction Heart Failure Diabetes Outcomes 61

Journal of the American Heart Association

FEBRUARY 19, 2025

Journal of the American Heart Association, Ahead of Print. BackgroundLimited studies show an association between elevated total homocysteine (tHcy) and heart failure (HF) risk, but no studies have assessed whether this association differs by HF subtype.

Atherosclerosis 75

Atherosclerosis Heart Failure Preserved Ejection Fraction Diabetes 75

Cardiovascular Diabetology

AUGUST 11, 2024

We evaluated the prevalence of “heart stress” (HS) based on NT-proBNP cut-points proposed by the 2023 Consensus of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in asymptomati.

Blood Pressure 111

Blood Pressure Heart Failure Hypertension Diabetes 111

Cardiovascular Diabetology

MARCH 21, 2025

Heart failure (HF) with preserved ejection fraction (HFpEF) is increasingly prevalent worldwide due to aging and comorbidities. Epicardial adipose tissue (EAT), favored by diabetes and obesity, was shown to co.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Obesity Diabetes 52

Cardiovascular Diabetology

OCTOBER 22, 2024

Hypertension (HTN) and diabetes mellitus (DM) are two common comorbidities of heart failure with reduced ejection fraction (HFrEF), each of which can cause right ventricular (RV) dysfunction. The aim of this s.

Heart Failure 52

Heart Failure Hypertension Diabetes Research 52

Science Daily - Heart Disease

JUNE 23, 2024

Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. Women experienced greater weight loss and the same symptom benefits compared with men.

Obesity 104

Obesity Heart Failure Diabetes 104

Open Heart

MAY 23, 2024

Pre-eclampsia and heart failure have common risk factors, including hypertension, obesity and diabetes. It is not known whether heart failure increases the risk of pre-eclampsia. This study examines whether pregestational heart failure increases the risk of pre-eclampsia.

Heart Disease 98

Heart Disease Heart Failure Risk Factors Obesity 98

Open Heart

DECEMBER 13, 2022

Aims The aim of this study was to investigate a real-world heart failure (HF) cohort regarding (1) prevalence of known diabetes mellitus (DM), undiagnosed DM and pre-diabetes, (2) if hf treatment differs depending on glycaemic status and (3) if treatment of DM differs depending on HF phenotype.

Diabetes 52

Diabetes Heart Failure Echocardiogram Hospital 52

Cardiovascular Diabetology

MARCH 25, 2025

Heart failure (HF) is increasingly recognized as a heterogeneous cardiometabolic disorder, often in the context of overweight/obesity independently from diabetes. Sodium-glucose cotransporter-2 inhibitors (SGL.

Heart Failure 52

Heart Failure Obesity Diabetes 52

Frontiers in Cardiovascular Medicine

FEBRUARY 27, 2024

However, this comes at a cost with more women developing diabetes, hypertension and coronary artery disease as they age. These traditional cardiovascular risk factors not only increase their lifetime risk of heart failure but also their overall risk of cancer. Women continue to enjoy a greater life expectancy than men.

Heart Failure 59

Heart Failure Cancer Coronary Artery Disease Article 59

Frontiers in Cardiovascular Medicine

DECEMBER 17, 2023

These conditions have an increasing share in the health burden worldwide due to worsening endemic of hypertension, obesity, and diabetes. However, the same set of genes were significantly induced in the Trp53inp2-cKO hearts under both mechanical and metabolic stresses.

Heart Failure 64

Heart Failure Diet Obesity Diabetes 64

Frontiers in Cardiovascular Medicine

NOVEMBER 17, 2024

BackgroundAnemia is a common complication in patients with heart failure and is associated with left ventricular systolic dysfunction.

Preserved Ejection Fraction 59

Preserved Ejection Fraction Heart Failure Tricuspid Atrial Fibrillation 59